Hikma Pharmaceuticals PLC
HKMPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,658,000 | $1,558,000 | $1,569,000 | $1,448,000 |
| % Growth | 6.4% | -0.7% | 8.4% | – |
| Cost of Goods Sold | $933,000 | $899,000 | $813,000 | $756,000 |
| Gross Profit | $725,000 | $659,000 | $756,000 | $692,000 |
| % Margin | 43.7% | 42.3% | 48.2% | 47.8% |
| R&D Expenses | $73,000 | $77,539 | $61,000 | $85,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $278,000 | $382,000 | $280,000 | $424,669 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $115,000 | -$61,539 | $64,000 | $58,331 |
| Operating Expenses | $466,000 | $398,000 | $405,000 | $568,000 |
| Operating Income | $259,000 | $261,000 | $351,000 | $122,000 |
| % Margin | 15.6% | 16.8% | 22.4% | 8.4% |
| Other Income/Exp. Net | $36,000 | -$94,000 | -$63,000 | -$43,000 |
| Pre-Tax Income | $295,000 | $167,000 | $288,000 | $79,000 |
| Tax Expense | $55,000 | $34,000 | $59,000 | $18,000 |
| Net Income | $238,000 | $133,000 | $226,000 | $59,000 |
| % Margin | 14.4% | 8.5% | 14.4% | 4.1% |
| EPS | 1.08 | 0.6 | 1.02 | 0.26 |
| % Growth | 80% | -41.2% | 292.3% | – |
| EPS Diluted | 1.07 | 0.6 | 1.01 | 0.27 |
| Weighted Avg Shares Out | 222,430 | 221,850 | 223,762 | 226,448 |
| Weighted Avg Shares Out Dil | 222,430 | 223,038 | 223,762 | 222,737 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,235 | -$32,167 | $3,998 | $4,064 |
| Interest Expense | $42,348 | $0 | $43,983 | $43,686 |
| Depreciation & Amortization | $102,000 | $82,000 | $97,000 | $35,000 |
| EBITDA | $476,000 | $288,000 | $499,000 | $345,000 |
| % Margin | 28.7% | 18.5% | 31.8% | 23.8% |